This report studies the global Interferon Alpha-2a Biosimilar market status and forecast, categorizes the global Interferon Alpha-2a Biosimilar market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa).
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
The global average price of Interferon Alpha-2a Biosimilar is in the decreasing trend, from 186.78 USD/Unit in 2013 to 64.67 USD/Unit in 2017. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Interferon Alpha-2a Biosimilar includes ordinary type and long-lasting type, and the proportion of ordinary type in 2017 is about 64%, and the proportion is in increasing trend from 2013 to 2017.
Interferon Alpha-2a Biosimilar is widely used for hepatitis C, hepatitis B and other diseases. The most proportion of Interferon Alpha-2a Biosimilar is used for hepatitis C, and the proportion in 2017 is 46%.
Europe is the largest supplier of Interferon Alpha-2a Biosimilar, with a production market share nearly 70% in 2017.
South America is the largest consumption place, with a consumption market share nearly 26% in 2017. Following South America, Europe is the second largest consumption place with the consumption market share of 22%.
Market competition is not intense. Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, 3sbio, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Interferon Alpha-2a Biosimilar market is valued at 390 million US$ in 2017 and will reach 150 million US$ by the end of 2025, growing at a CAGR of -11.0% during 2018-2025.
The major manufacturers covered in this report
Rhein Minapharm Biogenetics
Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
Other regions (Central & South America, Middle East & Africa)
We can also provide the customized separate regional or country-level reports, for the following regions:
Rest of Asia-Pacific
Rest of Europe
Central & South America
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
By Application, the market can be split into
The study objectives of this report are:
To analyze and study the global Interferon Alpha-2a Biosimilar capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);
Focuses on the key Interferon Alpha-2a Biosimilar manufacturers, to study the capacity, production, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strate